ReviewCurrent medicinal chemistry2025
LncRNA XIST: A Breakthrough in Inflammation-related Diseases.
Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- SETD7-mediated epigenetic regulation of LncRNA XIST promotes trophoblast pyroptosis: a study in preeclampsia mouse and cell models.Biology direct · 2026Article
- Upregulated lncRNA XIST drives trophoblast dysfunction through targeting miR-545-5p/POU2F1 axis in recurrent spontaneous abortion.American journal of translational research · 2026Article
- Single-cell transcriptomic atlas of taste papilla aging.Aging cell · 2024Article
- The in vivo effects of knockdown of long non-coding RNA XIST on fibroid growth and gene expression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- XIST and MUC1-C form an auto-regulatory pathway in driving cancer progression.Cell death & disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLong non-coding RNA (LncRNA) is a type of non-coding RNA that plays an important role in the body and accounts for the majority of RNA, and this non-coding RNA can regulate disease onset and progression with its wide range of functions. LncRNA Xist, also known as the long non-coding RNA X inactive specific transcript, is a member of them. It can regulate the development of organismal diseases by acting downstream on specific target genes. In addition to this, it can also influence disease onset and progression by acting on apoptosis, migration, invasion, and other processes. It has been shown that XIST plays an important role in the development of inflammation.
objectiveTo explore the role played by XIST in inflammation-related diseases and to explore its mechanism of action.
methodsThis paper summarizes and analyzes the role played by XIST in inflammation- related diseases by conducting a search in PubMed.
conclusionIn this paper, we summarize the mechanism of action of XIST in different types of inflammation-related diseases and propose new protocols for the future clinical treatment of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.